19 assets in Spinal Cord Injury

Therapeutic assets addressing Spinal Cord Injury, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Brivaracetam Spinal Cord Injury	University of Minnesota	P3	BB (68)
Lidocaine Spinal Cord Injury	University of Texas Rio Grande Valley	P2	BB (64)
Nabilone Spinal Cord Injury	Eldon Loh, MD	P3	BB (64)
Galantamine Hydrobromide Spinal Cord Injury	Northwell Health	P2/3	CCC (55)
Naltrexone Spinal Cord Injury	Medical College of Wisconsin	P2	CCC (53)
Cannabidiolic Acid Spinal Cord Injury	University of Miami	P1/2	CC (47)
Mtr-601 Spinal Cord Injury	Motric Bio	P1	CC (47)
Teonanacatl Spinal Cord Injury	James J. Peters Veterans Affairs Medical Center	P1/2	CC (45)
[ 18f]3f4ap Spinal Cord Injury	Yale University	P1	CC (43)
ec5026 Spinal Cord Injury	EicOsis Human Health Inc.	P1	CC (43)
mk-6240 Spinal Cord Injury	Yale University	P1	CC (43)
Pittsburgh Compound B Unlabelled Spinal Cord Injury	Yale University	P1	CC (43)
Allogeneic Umbilical Cord Blood Spinal Cord Injury	The Medical Pavilion Bahamas	Early P1	C (39)
Gentamicin Spinal Cord Injury	Medstar Health Research Institute	Early P1	C (38)
Lactobacillus Rhamnosus Gg Spinal Cord Injury	Medstar Health Research Institute	Early P1	C (38)
Bont Injections Spinal Cord Injury	Vastra Gotaland Region	N/A	D (30)
Throcalcitonin Spinal Cord Injury	Tanta University	N/A	D (30)
Zoledronate Spinal Cord Injury	University of Ioannina	N/A	D (30)
Botulinum B Toxin Spinal Cord Injury	Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC	P4	NR ()